Steady‐State Pharmacokinetic Properties of TNX‐102 SL, a Sublingual Tablet Formulation of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing in Healthy Volunteers: A Randomized, Open‐Label Trial
were 140% and 152%, respectively. Sublingual tablets and oral ER capsules had comparable metabolic profiles of Phase I and II metabolites in plasma over 20 days, with no unique metabolites by the sublingual route. Sublingual cyclobenzaprine HCl tablets were generally safe and well-tolerated.
Authors
- Seth Lederman (ORCID: https://orcid.org/0000-0003-2781-1455)
- Gregory M. Sullivan (ORCID: https://orcid.org/0000-0002-1707-4490)
- Bruce L. Daugherty
- Errol Gould
- Bernd Meibohm
Institutions
- University of Tennessee Health Science Center (US)
- Cyclacel Pharmaceuticals (United States) (US)
- MEMX (United States) (US)
Publication Details
- Journal
- Clinical Pharmacology in Drug Development
- Published
- 2026-04-01
- DOI
- https://doi.org/10.1002/cpdd.70060
- Primary Topic
- Pharmaceutical studies and practices
- Type
- article
- Field-Weighted Citation Impact
- 0.00